Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over

Table 3 Uni- and multivariate analyses of pre-treatment factors contributing to sustained virological response

	Univariate			Multivariate
Factors	P value	OR	95%CI	P value	OR	95%CI
Age, per 1-yr increase	0.782	0.991	0.931-1.055
≥ 75 yr	0.874	1.144	0.217-6.022
Sex, female	0.977	1.023	0.224-4.663
Height, per 1-cm increase	0.316	0.957	0.879-1.043
Weight, per 1-kg increase	0.568	0.982	0.924-1.044
BMI, per 1-kg/m2 increase	0.929	0.990	0.792-1.238
Cirrhosis	0.214	0.382	0.084-1.743
CKD, eGFR > 60 mL/min/1.73 m2	0.569	0.616	0.116-3.266
History of HCC treatment	0.027	0.175	0.037-0.822	0.072	0.225	0.044-1.145
History of IFN-based therapy	0.763	0.774	0.146-4.091
HCV-RNA, per 1-logIU/mL increase	0.644	0.831	0.380-1.821
WBC in mm3	0.703	1.009	0.963-1.057
Hb, per 1-g/dL increase	0.196	1.411	0.837-2.380
Platelets, per 1 × 104/mm3 increase	0.790	0.984	0.873-1.109
AST, per 1-IU/L increase	0.552	1.007	0.983-1.033
ALT, per 1-IU/L increase	0.608	1.005	0.987-1.023
γ-GT, per 1-IU/L increase	0.490	1.007	0.987-1.027
AFP, per 1-ng/mL increase	0.004	0.955	0.926-0.985	0.015	0.959	0.926-0.992
eGFR, per 1-mL/min/1.73 m2 increase	0.124	1.036	0.990-1.083

γ-GT: γ-glutamyl transferase; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; CI: Confidence interval; CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; Hb: Hemoglobin; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HCV-RNA: Hepatitis C virus-ribonucleic acid; IFN: Interferon; OR: Odds ratio; WBC: White blood cells.